751475-53-3
751475-53-3 結(jié)構(gòu)式
基本信息
2-(5,6-二乙氧基-7-氟-1,3-二氫-1-亞氨基-2H-異吲哚-2-基)-1-[3-叔丁基-4-甲氧基-5-(4-嗎啉基)苯基]乙酮
2-(5,6-二乙氧基-7-氟-1,3-二氫-1-亞氨基-2H-異吲哚-2-基)-1-[3-(1,1-二甲基乙基)-4-甲氧基-5-(4-嗎啉)苯基]乙酮
CS-666
E 5555
Atopaxa
Atopaxar
ER 172594-00
Atopaxar (E 5555)
(943239-67-6) atopaxar
1-(3-(tert-Butyl)-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-7-fluoro-1-iminoisoindolin-2-yl)ethanone
1-(3-tert-butyl-4-Methoxy-5-Morpholino-phenyl)-2-(5,6-diethoxy-7-fluoro-1-iMino-1,3-dihydro-isoindol-2-yl)-ethanone
物理化學(xué)性質(zhì)
常見(jiàn)問(wèn)題列表
PAR-1
Atopaxar inhibits haTRAP (high-affinity thrombin receptor activating peptide) binding to PAR-1 on human platelet membranes in a concentration-dependent manner, with an IC
50
of 0.019 μM.
Atopaxar inhibits human platelet aggregation induced by thrombin or TRAP in a concentration-dependent manner.
Atopaxar does not inhibit PRP (platelet-rich plasma) aggregation induced by ADP, U46619, collagen, and PAR-4ap, up to a concentration of 20 μM.
Atopaxar (30-100 mg/kg; p.o.) causes a dose-dependent prolongation of the time to occlusion of the femoral artery in photochemically-induced thrombosis (PIT) guinea pigs model.
Atopaxar does not prolong bleeding time in guinea pigs at the highest tested dosage of 1000 mg/kg.
| Animal Model: | Guinea pigs, PIT model |
| Dosage: | Oral administration |
| Administration: | 10 mg/kg, 30 mg/kg, 100 mg/kg |
| Result: | Prolonged the time to occlusion by 1.8-fold and 2.4-fold at 30 mg/kg and 100 mg/kg, respectively, compared with controls. |